Physician profile
Danielle Hughey
NPI 1205255148
$3,954.82
in general payments reported to CMS, 2019-2025
22 companies · $631 in 2025
The $631 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,137 · 2022: $963 · 2023: $618 · 2024: $605 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,854.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,505.20 | 2021-2025 | |
| Novo Nordisk INC | $605.86 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $546.49 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $170.36 | 2021-2022 | |
| Baxter Healthcare | $119.89 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $114.03 | 2021-2023 | Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $111.26 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.02 | 2022-2025 | Xifaxan, Trulance |
| Ibsa Pharma INC. | $76.24 | 2021-2024 | Tirosint, Licart |
| Biohaven Pharmaceuticals, INC. | $71.58 | 2021 | |
| Exact Sciences Corporation | $70.49 | 2023-2025 | Cologuard Collection Kit |
| Eisai INC. | $69.72 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $64.53 | 2022 | |
| Daiichi Sankyo INC. | $60.37 | 2021-2022 | |
| Glaxosmithkline, LLC. | $53.43 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $52.67 | 2021-2022 | |
| Astellas Pharma US INC | $39.63 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $37.04 | 2022-2023 | Belsomra |
| Allergan, INC. | $26.73 | 2021-2022 | |
| Esperion Therapeutics, INC. | $25.86 | 2021 | |
| Linus Health, INC. | $16.23 | 2022 | |
| Genentech USA, INC. | $14.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Hughey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.